Tonix Pharmaceuticals Will Present Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology
May 21, 2019 16:15 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, May 21, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) today announced that it will be presenting pharmacokinetic analyses of TNX-102...
Tonix Pharmaceuticals Announces Director Stepping Down
May 17, 2019 16:05 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, May 17, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced that Donald W. Landry, M.D., Ph.D., is stepping down from the Company’s Board of...
Tonix Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights
May 13, 2019 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, May 13, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company developing pharmaceutical products to...
Tonix Pharmaceuticals Announces New Board Member, Daniel Goodman, M.D., MBA
May 08, 2019 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, May 08, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) today announced the appointment of Daniel Goodman, M.D., MBA to its Board of Directors,...
Tonix Pharmaceuticals Announces Update on the Collaborative Research and Development Agreement (CRADA) with the U.S. Army Medical Materiel Development Activity (USAMMDA)
April 23, 2019 13:51 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, April 23, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), announced on April 18, 2019 that the Company received a notice of termination,...
Tonix Pharmaceuticals Announces that Breakthrough Therapy Designation Remains in Effect for Tonmya® for the Treatment of Posttraumatic Stress Disorder
April 22, 2019 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, April 22, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company developing pharmaceutical products...
Tonix Pharmaceuticals Plans to Expand TNX-102 SL Phase 3 Program Beyond PTSD to Include Fibromyalgia
April 04, 2019 07:30 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, April 04, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company focused on developing...
Tonix Pharmaceuticals to Present at Upcoming Investor Conferences
March 25, 2019 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, March 25, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Company management will present at two upcoming investor...
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights
March 18, 2019 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Phase 3 RECOVERY Trial of Tonmya® for the Treatment of PTSD Initiated and Enrolling Topline Data Expected First Half 2020 NEW YORK, March 18, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding...
Tonix Pharmaceuticals to Participate at Upcoming Investor Conferences
March 12, 2019 07:30 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, March 12, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Company management will participate and host investor...